Tango Therapeutics (TNGX) EBITDA (2020 - 2026)

Tango Therapeutics' EBITDA history runs 7 years deep, the most recent figure standing at -$48.8 million for Q1 2026.

• In Q1 2026, EBITDA fell 14.67% year-over-year to -$48.8 million; the TTM figure through Mar 2026 stood at -$27.6 million (up 81.1% YoY), while the FY2025 annual figure was -$101.7 million, up 21.86% from the prior year.
• EBITDA was -$48.8 million for Q1 2026 at Tango Therapeutics, down from $48.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $48.1 million in Q4 2025 to a low of -$48.8 million in Q1 2026.
• Historically, EBITDA has averaged -$24.8 million across 5 years, with a median of -$29.6 million in 2024.
• The sharpest annual moves came in 2022 and 2025: EBITDA sank 470.31% in 2022, then jumped 217.55% in 2025.
• A 5-year view of EBITDA shows it stood at -$27.9 million in 2022, then decreased by 7.12% to -$29.9 million in 2023, then slumped by 36.84% to -$40.9 million in 2024, then surged by 217.55% to $48.1 million in 2025, then slumped by 201.41% to -$48.8 million in 2026.
• The last three EBITDA figures came in at -$48.8 million (Q1 2026), $48.1 million (Q4 2025), and $14.1 million (Q3 2025), per Business Quant data.